HC Wainwright Has Negative Outlook for VTYX FY2029 Earnings

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Investment analysts at HC Wainwright cut their FY2029 earnings per share estimates for Ventyx Biosciences in a research note issued on Thursday, January 8th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.57) per share for the year, down from their previous estimate of ($1.50). HC Wainwright has a “Neutral” rating and a $14.00 price target on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.

Other equities research analysts also recently issued reports about the stock. Lifesci Capital restated a “market perform” rating and issued a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday. Wells Fargo & Company reissued an “equal weight” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a research note on Thursday. Oppenheimer downgraded Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday. Canaccord Genuity Group lowered Ventyx Biosciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $16.00 to $14.00 in a research report on Thursday. Finally, Clear Str cut Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Eight equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $14.86.

Ventyx Biosciences Price Performance

Shares of VTYX stock opened at $13.81 on Monday. The firm has a market cap of $985.48 million, a P/E ratio of -9.21 and a beta of 1.23. Ventyx Biosciences has a 1-year low of $0.78 and a 1-year high of $25.00. The firm’s 50-day simple moving average is $9.27 and its 200-day simple moving average is $5.32.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13.

Insider Buying and Selling at Ventyx Biosciences

In other news, insider John Nuss sold 12,675 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the transaction, the chief executive officer directly owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. 18.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VTYX. JPMorgan Chase & Co. boosted its position in shares of Ventyx Biosciences by 63.4% in the third quarter. JPMorgan Chase & Co. now owns 748,088 shares of the company’s stock worth $2,327,000 after buying an additional 290,169 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Ventyx Biosciences during the 3rd quarter valued at about $61,000. Woodline Partners LP acquired a new position in Ventyx Biosciences during the 3rd quarter worth approximately $143,000. XTX Topco Ltd boosted its holdings in Ventyx Biosciences by 25.2% in the 3rd quarter. XTX Topco Ltd now owns 202,382 shares of the company’s stock worth $629,000 after acquiring an additional 40,771 shares during the period. Finally, Vestal Point Capital LP boosted its holdings in Ventyx Biosciences by 2.5% in the 3rd quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock worth $6,376,000 after acquiring an additional 50,000 shares during the period. 97.88% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Ventyx Biosciences

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.